Exogenus Therapeutics - asvanced therapeutics through cell engineering

1. FEVEREIRO 2016
ADVANCED THERAPEUTICS THROUGH CELL ENGINEERING
CAIXA EMPREENDER AWARD

2. High probability
of infection
High risk of amputations
Frequent
treatments
Pain and impaired mobility

3. CARDIOVASCULAR
DISEASE
DIABETES
BED-BOUND
IMPAIRED
BLOOD
CIRCULATION
COMPROMISED
HEALING
CHRONIC WOUNDS
Do not heal for more
than 6 weeks
PROBLEM & NEED

4. Source: MedMarket Diligence, 2013
50 million chronic wound patients worldwide
Standard care is not
efficient in healing 70%
of these wounds
THE PROBLEM WE ARE
ADDRESSING
PROBLEM & NEED
Market growth driven by increased incidence of obesity and diabetes combined with an aging population.

5. The first s
derived gel for topic
application
N A N O in SPIRE
The first stem cell
derived gel for topic
lication in chronic
wounds
What is
Itisproduct
wounds
Blood ofhealth
potential.
abilityto
wound,
How can SKINHEALER
Accelerated healing
Lesstimespentinhospital
Reduced probability of
Fasterrecoveryof
N A N O in SPIRE
m cell
derived gel for topic
in chronic
What is SKINHEALER?
producttotreatdiabetic,venousandpressurechronic
wounds.Itispurifiedfromstemcellsofthe
ofhealthydonors,whichconfers
potential.ThemajorcomponentofSKINHEALER
tostimulatevascularizationandre
wound,rapidlystimulatingthehealing.
What does
SKINHEALER
chronic skin wounds
diseaseconditions:
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;
ulcers,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers
woundsoccurringonthefeetofdiabetics
How can SKINHEALER help me?
ccelerated healing,andthepossibilityofdoing
Lesstimespentinhospital,andlower cost
Reduced probability of internment,infection
Fasterrecoveryofmobilityandimproved quality of life
treatdiabetic,venousandpressurechronic
oftheUmbilical Cord
,whichconferstoitahighregenerative
SKINHEALER hasthe
ationandre-epithelizationofthe
.
does SKINHEALER do?
SKINHEALER accelerates the healing of
chronic skin wounds,whichresultfromdifferent
diseaseconditions:pressure ulcers,whichare
causedbyunrelievedpressureresultingin
damagetounderlyingtissue;venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
diabetic ulcers whicharetypicallychronic
ringonthefeetofdiabetics,dueto
inefficientbloodcirculation.
help me?
ossibilityofdoingself application.
lower costs duetofasterrecovery.
infectionandamputation.
improved quality of life
ing of
,whichare
causedbyunrelievedpressureresultingin
venous stasis
,whichdevelopasaresultofinsufficient
flowofbloodthroughveinsincertainareas;
whicharetypicallychronic
,dueto
REGENERATIVE
Thegelis
composedofstem
cellderived
componentswhich
deliverregenerative
factorstothe
injuredtissue.
SELF
ADMINISTERED
Itistheonlyproductin
themarketforthe
treatmentofchronic
woundsthatcanbe
selfadministered
uponmedical
counseling
CELLFREE
ADVANCEDTHERAPY
Itistheonlycell-free
AdvancedTherapy
Productinthemarket
forthetreatmentof
chronicwounds.
SELF
D
roductin
themarketforthe
ofchronic
thatcanbe
administered,
uponmedical
counseling.
Umbilical Cord Blood
CHALLENGE: Use of Stem Cells components for the treatment of Chronic Wounds
TECHNOLOGY
External manipulation to
increase the activity
Non-Cellular
Product with High
Therapeutic Activity
EXO-101
“I have trouble believing that stem cells will survive the harsh environment of the wound.”
Professor Martins-Green, Board of Directors of the Wound Healing Society
In collaboration with

6. Complete healing in
15 days
Accelerates
Healing
Promotes
Vascularization
Stimulates Skin
Growth
CONTROL
EXO-101
DAY 0 DAY 10
TECHNOLOGY VALIDATION
100% mice responded
to treatment
Wound size half of control
after 10 days
EXO-101

7. 50% improvement
when compared
with control
treatment
Significant
improvement
from DAY 2
Signigficant
improvement
from DAY 6
TECHNOLOGY DIFFERENTIATION

8. MAJOR ACHIEVEMENTS
EXOGENUS THERAPEUTICS
founded in June 2015
€100K pre-seed investment
by Caixa Capital
Young Entrepreneur
Award 2015 by ANJE
€800K seed investment by Caixa
Capital and Change Partners

9. MILESTONES STATUS
Business Plan
Seed Fund
Development of pre-clinical strategy
Product Development
Seek non-dilutive funding
Developing at the right pace

10. ROADMAP & FUTURE MILESTONES
2015 2016 2017 2018 2019 2020
SEED FUND
€900K €1.2M
Approval of
Clinical Trial
Product formulation
GLP animal tests
GMP production
IND submission
Funding Round A
POSSIBLE EXIT 1 Results
Clinical Trial
Phase I/II
POSSIBLE EXIT 2
€7.5M
Phase I Clinical Trial
Phase II Clinical Trial
Equity + Convertible Note
Cap Table:
Founders – 54%
Investors – 36%
ESOP – 10%

11. BOARD MEMBERS
David MaltaJoana Correia
Founder
Pedro Vilarinho Pedro Pinheiro

12. TEAM & PARTNERS
Luísa Marques, MBA
Chief Operations Officer
Ricardo Neves, PhD
Scientific Consultant
Joana Simões Correia, PhD
Chief Scientific Officer
Renato Cardoso, PhD
Head of Laboratory

13. Your life, back in your hands.

14. team@exogenustherapeutics.com
www.exogenustherapeutics.com